Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report

An artist in residence (she can afford)

Jun 24, 2019

Latest Episodes

Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Tech
Download
HTML Embed
HTML EMBED
Click to Copy
Make Me Smart with Kai and Molly
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace

Alzheimer’s database will help lower research costs

Nancy Marshall-Genzer Jun 11, 2010
Share Now on:
HTML EMBED:
COPY

by Nancy Marshall Genzer

A coalition of drug companies is releasing a new database on Alzheimer’s disease today to help lower research and development costs and get drugs the market faster. The new database includes information on 11 clinical trials, involving 4,000 Alzheimer’s patients.

The FDA and researchers around the world will have access to the information, including patient MRIs and scores from mental acuity tests. Big pharma groups like GlaxoSmithKline and Pfizer pooled their funding for the project with cooperation from the Food and Drug Administration.

Doctor Raymond Woosley, who heads the Critical Path Institute which helped create the database, says the database will give drug developers a head start. “You can find out if a drug is really working, without having to do a five-year trial,” he says.

Since the FDA will be using the same database, it may take less time to get new drugs approved — and be less costly. Woosley says it costs a lot for drugmakers to create new medications working on their own. “The failure rate during development, the cost of development, have created a real untenable business model,” he says.

Drug companies are usually reluctant to share the results of years of expensive research, according to Woosley. They’re also wary of antitrust laws. But lawyers have signed off on the new database, and another one is already in the works for Parkinson’s disease.

If you’re a member of your local public radio station, we thank you — because your support helps those stations keep programs like Marketplace on the air.  But for Marketplace to continue to grow, we need additional investment from those who care most about what we do: superfans like you.

Your donation — as little as $5 — helps us create more content that matters to you and your community, and to reach more people where they are – whether that’s radio, podcasts or online.

When you contribute directly to Marketplace, you become a partner in that mission: someone who understands that when we all get smarter, everybody wins.